NP 202 - Armaron Biosciences

Drug Profile

NP 202 - Armaron Biosciences

Alternative Names: NP 202 - Neuprotect; NP-202 - NeuProtect

Latest Information Update: 17 Jul 2015

Price : $50

At a glance

  • Originator NeuProtect
  • Developer Armaron Biosciences
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders

Most Recent Events

  • 26 Jun 2015 Armaron Biosciences plans a phase II trial in Myocardial infarction in Australia and New Zealand (ACTRN12615000609550)
  • 10 Jun 2014 Phase-I clinical trials in Cardiovascular disorders (Prevention, In volunteers) in Australia (PO)
  • 02 Apr 2014 Preclinical trials in Cardiovascular disorders (prevention) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top